Neutrocytopenia associated with a lurasidon therapy in a patient with paranoid schizophrenia
Introduction Lurasidon is a relatively new, second-generation antypsychotic drug with an interesting receptor profile. It is considered safe and has a low risk of side effects. This drug is effecitve in reducing the productive symptoms of schizophrenia, but also has a positive effect on negative sy...
Main Authors: | Z. Mielczarek, B. Trędzbor, K. Krysta |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2023-03-01
|
Series: | European Psychiatry |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823022617/type/journal_article |
Similar Items
-
Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy
by: Miura I, et al.
Published: (2023-09-01) -
Biosocial characteristics of patients with paranoid schizophrenia
by: Gergana K. Panayotova, et al.
Published: (2016-04-01) -
Electroconvulsive therapy in a patient with resistant paranoid schizophrenia treated with clozapine
by: S. Castelao-Almodóvar, et al.
Published: (2021-04-01) -
Therapy of Schizoaffective Disorder and Paranoid Schizophrenia with Episodic Course
by: L. A. Ivanova, et al.
Published: (2019-05-01) -
Lurasidone for the treatment of schizophrenia in adult and paediatric populations
by: Teresa Guilera, et al.
Published: (2023-02-01)